Publication

Back to overview

Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author RačkayováVeronika, Flatt Emmanuelle, BraissantOlivier, GrosseJocelyn , CapobiancoDaniela, MastromarinoPaola, McMillinMatthew , DeMorrow Sharon , McLinValérie A, CudalbuCristina,
Project Translational Non-Invasive Metabolic Studies towards Novel Treatments of Chronic Hepatic Encephalopathy in Developing Brain, from 3D Organotypic Brain Cell Cultures to the In vivo Rat and Human Brain
Show all

Original article (peer-reviewed)

Journal Sci Rep
Volume (Issue) 11(1)
Page(s) 2269
Title of proceedings Sci Rep
DOI 10.1038/s41598-021-81871-8

Open Access

URL https://pubmed.ncbi.nlm.nih.gov/33500487/
Type of Open Access Publisher (Gold Open Access)

Abstract

Chronic liver disease leads to neuropsychiatric complications called hepatic encephalopathy (HE). Current treatments have some limitations in their efficacy and tolerability, emphasizing the need for alternative therapies. Modulation of gut bacterial flora using probiotics is emerging as a therapeutic alternative. However, knowledge about how probiotics influence brain metabolite changes during HE is missing. In the present study, we combined the advantages of ultra-high field in vivo 1H MRS with behavioural tests to analyse whether a long-term treatment with a multistrain probiotic mixture (VIVOMIXX) in a rat model of type C HE had a positive effect on behaviour and neurometabolic changes. We showed that the prophylactic administration of this probiotic formulation led to an increase in gut Bifidobacteria and attenuated changes in locomotor activity and neurometabolic profile in a rat model of type C HE. Both the performance in behavioural tests and the neurometabolic profile of BDL + probiotic rats were improved compared to the BDL group at week 8 post-BDL. They displayed a significantly lesser increase in brain Gln, a milder decrease in brain mIns and a smaller decrease in neurotransmitter Glu than untreated animals. The clinical implications of these findings are potentially far-reaching given that probiotics are generally safe and well-tolerated by patients.
-